- Global Pharma News & Resources

Obesity Management Market is predicted to grow at 5.1% CAGR through 2032

The global obesity management market is projected to reach a valuation of US$ 1,362.80 Million in 2032, with the market expanding at a moderate CAGR of 5.1% over the forecast period of 2022 to 2032. Valued at an estimated US$ 828.71 Million in 2022, the obesity management market is driven by the steep incline in the incidences of obesity and obesity related health issues. An escalation in the obese pollution has resulted in high demand for obesity management programmes. This bodes well for the the obesity management market over the forecast period.

With rising number of bariatric surgeries along with an increase in adoption of online weight loss and weight management programmes, growth in the disposable income in emerging economies, sedentary lifestyle and favorable government initiatives, awareness among the obese population has also increased. Along with this awareness, there’s been a notable increase in the demand for obesity management.

Get Sample PDF of the Report@

In most developed countries with increasing geriatric population, owing to better healthcare facilities and a resultant increased life expectancy, the obesity management market has witnessed a considerable growth. As the elderly population is highly susceptible to gaining noticeable body fat and losing muscle mass and functioning ability, this age group of the population is a major market drive both in the short and long term. Additionally, genetics and medication side effects that lead to obesity also contribute to the market growth.

In spite of facing positive future market prospects, the target market is not without its share of challenges. High costs of surgeries and drugs coupled with safety issues may hinder the progress of the obesity management market in the global space over the forecast period.

“Prevailing sedentary lifestyle results in a surge in obese population which, in turn, is expected to propel the market growth of obesity management over the forecast period,” says an FMI analyst.  

Key Takeaways:

  • Rising adoption of weight loss and weight management programs to drive market growth.
  • Concerns about the safety of obesity management drugs may hamper the market growth.
  • Liraglutide registered the largest market share of 32.4%.
  • By surgery type, gastric sleeve surgery is expected to dominate the market.
  • The US is expected to maintain a high growth rate over the forecast period.
  • The obesity management market in Europe to contribute significantly to the global revenue.

Speak to our Research Expert@

Competitive Landscape 

GlaxoSmithKline Plc, VIVUS, Inc., Novo Nordisk A/S, Currax Pharmaceuticals LLC, Cheplapharm Arzneimittel GmbH, Bausch Health Companies Inc., and Takeda Pharmaceuticals, Inc. and others, are some of the major players in the obesity management market that are profiled in the full version of the report.

In a consolidated market, major players are increasing investment in research and development activities for product innovation, development and upgradation of existing products.

More Insights into the Obesity Management Market Report

According to the latest FMI reports, based on region, the obesity management market in North America is predicted to undergo remarkable growth over the assessment period. The regional market is primarily driven the target market’s growth in the US The US, is expected to maintain a high growth rate over the assessment period. Growing incidences of obesity and associated diseases coupled with the presence of major market players will drive the market growth in North America.

Apart from North America, Europe and the Asia Pacific are also anticipated considerable growth of the market. Heightened consumption of processed meat is increasing obesity cases in Europe which results in a healthy target market. Asia Pacific is emerging as a lucrative market opportunity for obesity management programs.

Based on segmentation, by drug type, the Liraglutide segment is expected to dominate the market while gastric sleeve surgery will lead the market growth on the basis of surgery type.

Key Segments

By Drug Type:

  • Bupropion and Naltrexone
  • Orlistat
  • Lorcaserin
  • Phentermine and Topiramate
  • Liraglutide

By Surgery Type:

  • Gastric Bypass Surgery
  • Adjustable Gastric Banding Surgery
  • Gastric Sleeve Surgery
  • Duodenal Switch Surgery
  • Others

By Distribution Channel:

  • Hospitals Pharmacies
  • Retail Pharmacies
  • E-commerce

Buy Complete Report@

About Future Market Insights (FMI)

Future Market Insights (ESOMAR certified market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favor the market growth in various segments on the basis of Source, Application, Sales Channel and End Use over the next 10-years.


Future Market Insights, Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries:
Browse All Reports:

Editor Details

Last Updated: 13-Feb-2023